Position
Fidelity in Ascendis Pharma A/S
Back to the book · All holders of ASND
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $134.7M$228.73 → $266.72
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 4.15M | $885.7M | — | — | — | 0.0% |
| Q1 2026 | 3.88M | $886.7M | $228.73 | $60M | −$59M | 0.0% |
| Q2 2026 | 3.55M | $945.7M | $266.72 | $134.7M | −$75.7M | 0.0% |